This application to renew our participation in the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreas Cancer (CPDPC), will enable the Stanford Clinical Center to continue its productive recruitment of patients into four key clinical studies of the consortium ? 1) Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies (PROCEED), 2) Pediatric Longitudinal Cohort Study of Chronic Pancreatitis [The International Study Group of Pediatric Pancreatitis: In Search for a Cure (INSPPIRE2), 3) Prospective Study to Establish a New Onset Diabetes Cohort (NOD), and 4) Evaluation of a mixed meal test for Diagnosis and characterization of Pancreaticogenic Diabetes secondary to pancreatic cancer and chronic pancreatitis (DETECT). Prospectively collected specimens from these studies will be used to further examine the role of the immune system in chronic pancreatitis and its relationship to the development of diabetes and pancreas cancer. In response to the research objectives of the CPDPC Consortium as outlined in this RFA, we have formed a strong scientific team with broad complementary expertise in clinical adult and pediatric pancreatitis, endocrinology, radiology, primary care, and immunology. Our proposal is highly responsive to the RFA in several specific ways. As part of the original Consortium, our Clinical Center, has demonstrated capacity to effectively recruit patients into 4 primary studies of the CPDPC. We have successfully used archived specimens to demonstrate potential immune signals to diagnose chronic pancreatitis and pancreatic cancer. In this renewed proposal, we intend to continue to validate these studies using prospectively collected samples from the prospective longitudinal cohorts of this consortium. We hope to ultimately develop and validate cytokine profiles that may facilitate diagnosis of chronic pancreatitis, predict likelihood of associated complications, and lead to targets to support clinical trials to halt fibrosis. For pancreas cancer, these studies may lead to novel diagnostic tests to detect pancreatic cancer at earlier stages. The opportunity to further investigate and validate these novel observations in collaboration with other centers remains an exciting opportunity to change diagnosis and patient management for chronic pancreatitis and its associated complications of pancreatogenic diabetes and pancreas cancer development.
The Stanford Clinical Center will continue to lead and actively participate in the research objectives of the Chronic Pancreatitis, Diabetes, and Pancreas Cancer (CPDPC) Consortium by recruiting into the 4 key clinical studies. Collected specimens from these studies will be studied to develop and validate new immunological insights into how chronic pancreatitis progresses and complications develop including diabetes and pancreas cancer. These insights will inform new diagnostic tests and treatments.
Showing the most recent 10 out of 12 publications
